{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:54:39Z","timestamp":1788292479964,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bulcan.2019.12.006","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T08:02:47Z","timestamp":1579680167000},"page":"10-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pr\u00e9venir les cancers\u00a0: place de la vaccination Papillomavirus en population g\u00e9n\u00e9rale"],"prefix":"10.1016","volume":"107","author":[{"given":"Fran\u00e7ois","family":"Vi\u00e9 le Sage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bulcan.2019.12.006_bib0250","first-page":"1","article-title":"Cancers induits par les papillomavirus humains","volume":"XXVIII","author":"Favre","year":"2013","journal-title":"La lettre de l\u2019infectiologue"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.bulcan.2019.12.006_bib0255","doi-asserted-by":"crossref","first-page":"F34","DOI":"10.1016\/j.vaccine.2012.05.070","article-title":"Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis","volume":"30","author":"Gillison","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.bulcan.2019.12.006_bib0260","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ijc.24339","article-title":"Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?","volume":"125","author":"N\u00e4sman","year":"2009","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2019.12.006_bib0265","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0028-2243(95)02303-A","article-title":"Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV)","volume":"65","author":"Syrj\u00e4nen","year":"1996","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"10.1016\/j.bulcan.2019.12.006_bib0270","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00004347-199307000-00001","article-title":"Studies on 200\u00a0cases of early squamous cell carcinoma of the cervix","volume":"12","author":"Ost\u00f6r","year":"1993","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0275","doi-asserted-by":"crossref","first-page":"g130","DOI":"10.1136\/bmj.g130","article-title":"Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomized controlled trial","volume":"348","author":"Elfstr\u00f6m","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0280","series-title":"Donn\u00e9es \u00e9pid\u00e9miologiques sur le cancer du col de l\u2019ut\u00e9rus Etat des connaissances. Rapport INVS 01\/2007","author":"Duport","year":"2007"},{"issue":"5","key":"10.1016\/j.bulcan.2019.12.006_bib0285","doi-asserted-by":"crossref","first-page":"e61825","DOI":"10.1371\/journal.pone.0061825","article-title":"A randomized, obseruer blinded lm munogenicity trial of Cervarix@ and Gardasil@ Human Papillomavirus vaccines in 12\u201315\u00a0year old girls","volume":"8","author":"Draper","year":"2013","journal-title":"PLoS ONE"},{"issue":"10108","key":"10.1016\/j.bulcan.2019.12.006_bib0290","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16\u201326\u00a0years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bulcan.2019.12.006_bib0295","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2019.12.006_bib0305","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/infdis\/jiy075","article-title":"Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old Australian women 9\u00a0years following implementation of vaccination","volume":"217","author":"Machalek","year":"2018","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.bulcan.2019.12.006_bib0310","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-1902","article-title":"Human papillomavirus vaccine effectiveness and herd protection in young women","volume":"143","author":"Spinner","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0315","first-page":"544e547","article-title":"The near disappearance of genital warts in young women 4\u00a0years after commencing a national human papillomavirus (HPV) vaccination programme","volume":"87","author":"Tim","year":"2011","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0320","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.bulcan.2019.12.006_bib0325","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/infdis\/jiu370","article-title":"Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data","volume":"211","author":"Smith","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0330","series-title":"Cervical screening in Australia","year":"2018"},{"issue":"41","key":"10.1016\/j.bulcan.2019.12.006_bib0335","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737","article-title":"The impact of 10\u00a0years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?","volume":"23","author":"Patel","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0340","series-title":"Media statement March 3rd 2018","author":"Garland","year":"2018"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0345","first-page":"e19","article-title":"The projected timeframe until cervical cancer elimination in Australia: a modelling study","author":"Hall","year":"2018","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0350","doi-asserted-by":"crossref","first-page":"l1161","DOI":"10.1136\/bmj.l1161","article-title":"Prevalence of cervical disease at age 20\u00a0after immunisation with bivalent HPV vaccine at age 12\u201313\u00a0in Scotland: retrospective population study","volume":"365","author":"Palmer","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0355","first-page":"CD009069","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"32\u00a0Pt\u00a0A","key":"10.1016\/j.bulcan.2019.12.006_bib0360","first-page":"4783","article-title":"Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study","volume":"36","author":"Rengaswamy","year":"2018","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.bulcan.2019.12.006_bib0365","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/ijc.31231","article-title":"Vaccination protects against invasive HPV-associated cancers","volume":"142","author":"Luostarinen","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0370","first-page":"1","article-title":"Prophylactic vaccination against human papilloma viruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.bulcan.2019.12.006_bib0375","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/cid\/cir836","article-title":"The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization","volume":"54","author":"Skowronski","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.bulcan.2019.12.006_bib0380","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1542\/peds.2007-0167","article-title":"Childhood influenza: number needed to vaccinate to prevent 1\u00a0hospitalization or outpatient visit","volume":"120","author":"Lewis","year":"2007","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.bulcan.2019.12.006_bib0385","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","article-title":"Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data","volume":"11","author":"Donovan","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0390","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ajo.12227","article-title":"Offering HPV vaccination to women treated for high-grade cervical intra-epithelial neoplasia: what do you need to know?","volume":"54","author":"Brotherton","year":"2014","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"32","key":"10.1016\/j.bulcan.2019.12.006_bib0395","first-page":"698","article-title":"Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR"},{"issue":"37","key":"10.1016\/j.bulcan.2019.12.006_bib0400","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.vaccine.2013.06.057","article-title":"Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males","volume":"31","author":"Goldstone","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.bulcan.2019.12.006_bib0405","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0410","series-title":"HCSP Avis relatif aux recommandations vaccinales contre les infections \u00e0 HPV chez les hommes","year":"2016"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0415","unstructured":"Sant\u00e9 Publique France. Information sur l\u2019efficacit\u00e9 des vaccinations contre les infections \u00e0 HPV \u00e0 partir des donn\u00e9es en \u00ab\u00a0vie r\u00e9elle\u00a0\u00bb. 2019. http:\/\/www.espacecancer.sante-ra.fr\/Ressources\/Documents\/Information_HPV_VF.pdf."},{"issue":"4","key":"10.1016\/j.bulcan.2019.12.006_bib0420","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4161\/hv.22994","article-title":"A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France","volume":"9","author":"Bresse","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0425","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2407-13-10","article-title":"Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe","volume":"13","author":"Marty","year":"2013","journal-title":"BMC Cancer"},{"issue":"28","key":"10.1016\/j.bulcan.2019.12.006_bib0430","first-page":"393","volume":"92","author":"GACVS: Global Adisory Committee on vaccine safety","year":"2017","journal-title":"Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0460","series-title":"Vaccins anti-HPV et risque de maladies auto-immunes: \u00e9tude pharmaco\u00e9pid\u00e9miologique Rapport final","author":"ANSM\/CNAMTS","year":"2015"},{"issue":"13","key":"10.1016\/j.bulcan.2019.12.006_bib0435","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barr\u00e9 syndrome after human papilloma virus vaccine: a self-controlled case-series study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.bulcan.2019.12.006_bib0440","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.neurol.2019.01.022","article-title":"groupe fran\u00e7ais pour les recommandations dans la scl\u00e9rose en plaques (France4MS) de la soci\u00e9t\u00e9 francophone de la scl\u00e9rose en plaques (SFSEP). Vaccinations et scl\u00e9rose en plaques\u00a0: recommandations de la soci\u00e9t\u00e9 francophone de la scl\u00e9rose en plaques","volume":"175","author":"Lebrun","year":"2019","journal-title":"Rev Neurol"},{"issue":"19","key":"10.1016\/j.bulcan.2019.12.006_bib0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES.2019.24.19.1800380","article-title":"A cluster analysis of serious adverse event reports after human papillomavirus (HPV) vaccination in Danish girls and young women, September 2009\u00a0to August 2017","volume":"24","author":"Ward","year":"2019","journal-title":"Euro Surveill"},{"issue":"32","key":"10.1016\/j.bulcan.2019.12.006_bib0450","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2019.12.006_bib0455","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.respe.2010.06.165","article-title":"Economic burden of anal cancer management in France","volume":"58","author":"Abramowitz","year":"2010","journal-title":"Rev Epidemiol Sante Publique"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120300059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120300059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:32:03Z","timestamp":1757791923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455120300059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0007455120300059"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.12.006","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pr\u00e9venir les cancers\u00a0: place de la vaccination Papillomavirus en population g\u00e9n\u00e9rale","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}